Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ Brodalumab As The Lowest Priced Injectable Biologic For ModerateToSevere Plaque Psoriasis

LAVAL Quebec April 21 2017 PRNewswire Valeant Pharmaceuticals International Inc. NYSE VRX and TSX VRX today announced that following the evaluation and approval of its Patient Access and Pricing Committee PAPC the company has decided to list SILIQ brodalu...